IVX-411

IX-411
Vaccine description
Target	SARS-CoV-2
Vaccine type	Virus-like particles
Clinical data
Routes of; administration	Intramuscular

IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4]

References

"ANZCTR - Registration". anzctr.org.au. Retrieved 18 August 2021.
"Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc". investors.icosavax.com. Retrieved 18 August 2021.
"Two nanoparticle vaccines enter clinical trials". Institute for Protein Design. 2 June 2021. Retrieved 18 August 2021.
Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. (June 2021). "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity". Nature. 594 (7862): 253–258. Bibcode:2021Natur.594..253A. doi:10.1038/s41586-021-03530-2. PMID 33873199.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "ANZCTR - Registration". anzctr.org.au. Retrieved 18 August 2021.

[2] "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc". investors.icosavax.com. Retrieved 18 August 2021.

[3] "Two nanoparticle vaccines enter clinical trials". Institute for Protein Design. 2 June 2021. Retrieved 18 August 2021.

[4] Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. (June 2021). "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity". Nature. 594 (7862): 253–258. Bibcode:2021Natur.594..253A. doi:10.1038/s41586-021-03530-2. PMID 33873199.